PharmaJet partner Zydus Cadila seeks EUA on world’s first plasmid DNA COVID-19 vaccine

GOLDEN, Colo. — July 7, 2021 - PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila has applied for Emergency Use Authorization (EUA) to the office of the Drug Controller General of India (DCGI) for its plasmid DNA Vaccine against COVID-19. The vaccine, ZyCoV-D, will be exclusively administered using the PharmaJet Tropis® Needle-free Injection System. Zydus Cadila is a global pharmaceutical company based in India, that develops, manufactures, and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics, and vaccines.

The Lancet Publication Confirms Viability of Intradermal Polio Vaccination

GOLDEN, Colo. — June 3, 2021- A systematic review and meta-analysis published in the April 30, 2021 issue of The Lancet strengthens evidence from previous publications that fractional dose delivery is a viable alternative to full dose inactivated polio vaccine (IPV). Previous studies have shown that two doses of intradermally-delivered IPV (60% less vaccine) were more immunogenic than one full dose delivered intramuscularly. Intradermal fractional dose delivery also lowers the total cost of vaccination substantially.

PharmaJet presents Needle-free delivery of Covid-19 DNA vaccine results at World Vaccine Congress

GOLDEN, Colo. — April 27, 2021 — PharmaJet®, the maker of innovative, needle-free injection technology, announced that their latest research results will be presented at the World Vaccine Congress on May 6. The presentation, entitled Progress of COVID-19 Vaccines with Needle-Free Delivery, is being presented by Erin K. Spiegel, PhD, Vice President, Clinical & Regulatory Affairs at PharmaJet, Inc.

PharmaJet’s Needle-free System to be used in Australian Clinical COVID-19 Trial

GOLDEN, Colo. — October 6, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Stratis® Needle-free Injection System will be used to deliver a vaccine against SARS-CoV-2 in a clinical trial in Australia. The DNA-based vaccine COVIGEN was developed by French-Thai pharmaceutical company BioNet and Melbourne-based biotech Technovalia. The Phase 1 trial is a joint collaboration between Australia’s most experienced vaccine trial sites including the University of Sydney, the Telethon Kids Institute in Perth, the University of Adelaide, the Vax4COVID alliance, and with multi-million dollars financial support of Australia’s Medical Research Future Fund.